Maryland's Technology Development Corp. is dishing out funds for startups and early stage digital health companies. Overall, 15 med tech companies received a total of $1.5 million.
Regeneron is pouring more money than ever into its well-respected R&D operation, spending big on a cadre of late-stage candidates the Big Biotech believes can outshine its blockbuster eye treatment.
With small but prestigious contributions from the scientific community, SQZ Biotech is looking to launch its CellSqueeze platform to be used in commercial applications.
In new late-stage data, Novo Nordisk's inaugural obesity drug spurred statistically significant weight loss compared to placebo, bolstering the company's case as it works to build a portfolio of such treatments.
Medical device startup Force Impact Technologies designed a mouthguard that can provide real-time alerts on concussions during high-impact activities to coaches and medical professionals.
With generic and branded rivals inching up on AstraZeneca's blockbuster respiratory drug Symbicort, the pharma giant has a game plan locked, loaded and ready to go. The company sealed the deal for Almirall's respiratory portfolio, inheriting a couple of marketed drugs to expand its current offerings and a list of medications currently under development.
Bristol-Myers Squibb has grabbed an option on an early-stage program for idiopathic pulmonary fibrosis this morning, forging a deal to potentially buy out Denmark's Galecto Biotech for up to $444 million--if the drug pans out in the clinic.
Entrepreneur Jonathan Rothberg's startup company Butterfly Network is working on a new imaging device the size of an iPhone that you will be able to hold up to a person's chest and see real-time, 3-D images of their heart beating.
Princeton, NJ-based Advaxis has seen such encouraging results in dogs for one of its drug candidates, ADXS-cHER2, that it has embarked on a parallel development program: studying the drug in pediatric osteosarcoma, while partnering with Aratana Therapeutics to move the drug forward in canine osteosarcoma.
Google has made the biggest change to its Flu Trends influenza tracking software since it first released the system in 2008. The update incorporates data from the Centers for Disease Control and Prevention in an attempt to improve the accuracy of the model.